Table 2.

Sustained virologic response rate by genotype and regimen used

Genotype	Total Treated, N	Total with Sustained Virologic Response, N	Sustained Virologic Response Rate, %	Early Discontinuation, N (%)
Genotype 1Aa overall	54	45	83	3 (6)
Sofosbuvir/ribavirin ×24 wk	2	2	100
Sofosbuvir/simeprevir ×12 wk	32	25	78
Sofosbuvir/simeprevir ×24 wk	1	1	100
Sofosbuvir/ledipasvir ×12 wk	11	9	82
Sofosbuvir/ledipasvir ×24 wk	4	4	100
Sofosbuvir/ledipasvir/ribavirin ×12 wk	2	2	100
Sofosbuvir/simeprevir/ribavirin ×12 wk	2	2	100
Genotype 1B overall	18	16	89	2 (11)
Sofosbuvir/ribavirin ×12 wk	1	1	100
Sofosbuvir/ribavirin ×24 wk	2	1	50
Sofosbuvir/simeprevir ×12 wk	9	8	89
Sofosbuvir/ledipasvir ×12 wk	5	5	100
Sofosbuvir/simeprevir/ribavirin ×12 wk	1	1	100
Genotype 2	14	12	86	1 (7)
Sofosbuvir/ribavirin ×12 wk	14	12	86
Genotype 3	7	3	43	2 (28)
Sofosbuvir/ribavirin ×12 wk	1	0	0
Sofosbuvir/ribavirin ×24 wk	6	3	50
Genotype 4	5	3	60	0 (0%)
Sofosbuvir/ribavirin ×24 wk	2	1	50
Sofosbuvir/ledipasvir ×12 wk	3	2	67
Total	98	79	81	8 (8)

^aIncludes both genotype 1A and genotype 1 nonsubtypable.